EUVIMEDEUVIMED entdecken
Crossref

Population pharmacokinetics and probability of target attainment of tigecycline in critically ill children

Wenjuan Hu, Yawen Yuan, Boyu Tan, Qiaoling Yang, Yuelian Jiang, Yijun Li, Huajun Sun, Zhiling Li, Yun Cui, Joseph F Standing iD

Journal of Antimicrobial Chemotherapy · 05.05.2026 · 81 (6)

DOI: 10.1093/jac/dkag156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 05.05.2026. Verfasst von Wenjuan Hu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Tigecycline, Anti-Bacterial Agents, Bacterial Infections. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Chinese Pharmaceutical Association Hospital Pharmacy department, National Natural Science Foundation of China, UK Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Tigecycline is not usually recommended for patients under 18 years due to limited safety data and adverse events, and dosing guidelines for children under 8 remain undefined. However, it remains a critical treatment option for life-threatening multidrug-resistant infections in critically ill children. This study aimed to characterize the population pharmacokinetics (PopPK) of tigecycline in children, identify key covariates affecting PK variability and propose optimized dosing regimens tailored to specific infection types. Materials and methods This study enrolled 20 children receiving intravenous tigecycline. One- and two-compartment models were explored. Monte Carlo simulations with age-stratified tigecycline dosing regimens were performed to evaluate the probability of target attainment (PTA) for various dosing regimens.

Results

A two-compartment model incorporating allometric scaling and a sigmoidal maturation function best described tigecycline PK. PTA analyses indicated that the standard dose was sufficient for children with infections caused by susceptible Streptococcus groups (breakpoint 0.125 mg/L) across community-acquired pneumonia (CAP), complicated intra-abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI). For susceptible Enterobacterales, Staphylococcus spp. or Enterococcus spp. (breakpoint 0.5 mg/L), the standard dose reached PK/pharmacodynamic (PD) targets for CAP, while cIAI required twice the standard dose. cSSSI necessitated higher dosing (150 mg) in adolescents; however, potential toxicity concerns necessitate extreme caution with such escalation. Infections caused by Enterobacteriaceae with intermediate resistance (breakpoint 4 mg/L) failed to achieve PK/PD targets even with increased doses exceeding 4.8 mg/kg.

Conclusions

Overall, these results suggest that current dosing recommendations may be insufficient for less susceptible pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TigecyclineAnti-Bacterial AgentsBacterial InfectionsHumansCritical IllnessChild, PreschoolFemaleChildMaleInfantMonte Carlo MethodMicrobial Sensitivity TestsAdolescentIntraabdominal InfectionsCommunity-Acquired PneumoniaAdministration, Intravenous

Substanzen

TigecyclineAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Clinical Pharmacy, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
  • Department of Critical Care Medicine, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Infection, Immunity, Inflammation Section, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK.

ORCID-Profile: Joseph F Standing

Förderung

  • Chinese Pharmaceutical Association Hospital Pharmacy department
  • National Natural Science Foundation of China
  • UK Medical Research Council
  • Special Research Project Research on High-Quality Development of Hospitals and Pharmaceutical Innovation
  • National Pharmaceutical Service Research Project "Ju huo You cai"
  • National Pharmaceutical Service Research Project “Ju huo You cai”

Zitieren

APA

Hu, W., Yuan, Y., Tan, B., Yang, Q., Jiang, Y., Li, Y., Sun, H., Li, Z., Cui, Y., & Standing, J. F. (2026). Population pharmacokinetics and probability of target attainment of tigecycline in critically ill children. Journal of Antimicrobial Chemotherapy, 81(6). https://doi.org/10.1093/jac/dkag156

Vancouver

Hu W, Yuan Y, Tan B, Yang Q, Jiang Y, Li Y, et al. Population pharmacokinetics and probability of target attainment of tigecycline in critically ill children. Journal of Antimicrobial Chemotherapy. 2026;81(6). doi:10.1093/jac/dkag156

BibTeX
@article{Hu2026,
  author = {Hu, Wenjuan and Yuan, Yawen and Tan, Boyu and Yang, Qiaoling and Jiang, Yuelian and Li, Yijun and Sun, Huajun and Li, Zhiling and Cui, Yun and Standing, Joseph F},
  title = {Population pharmacokinetics and probability of target attainment of tigecycline in critically ill children},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {6},
  doi = {10.1093/jac/dkag156}
}
Kostenlos starten →